The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Delivanis on Pembrolizumab-Induced Thyroiditis

Danae Delivanis, MD
Published Online: 8:49 PM, Wed October 21, 2015

Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.

A retrospective comprehensive study looked at 94 patients, all who received the immune checkpoint inhibitor pembrolizumab for the treatment of their cancer, to determine how many experienced the side effect of thyroiditis.

In the study, the incidence of any thyroid abnormality was as high as 15%, says Delivanis. Of the 14 patients that experienced thyroid abnormality there were 7 cases of thyroiditis, 4 cases of new-onset or subclinical hypothyroidism, and three cases of recurrent hypothyroidism that required adjustments in treatment.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.